Acquired factor VII deficiency in hematopoietic stem cell transplant recipients

Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
Bone Marrow Transplantation (Impact Factor: 3.57). 04/2002; 29(5):403-8. DOI: 10.1038/sj.bmt.1703381
Source: PubMed


Acquired factor VII (FVII) deficiency in the absence of vitamin K deficiency, oral anticoagulant therapy, synthetic liver dysfunction, or DIC is rare, with only a handful of cases thus far reported. In the period from 1990 to 1996 we identified eight patients with acquired FVII deficiency, all of whom presented with prolongation of the prothrombin time (PT) in the first 2 weeks following stem cell transplantation (SCT). The mean plasma FVII clotting activity (FVII:c) was 22% (range 8-35%) with an approximately equivalent reduction in FVII antigen (FVII:Ag) level. Mean plasma levels of fibrinogen and factors II, V, IX, and X were normal. Protein C activity was significantly depressed in only one of the three patients in whom it was measured. Several patients experienced bleeding complications, and hemorrhage directly accounted for death in two cases. Veno-occlusive disease of the liver developed in three patients. We conclude that FVII deficiency should be considered in the differential diagnosis of prolonged PT in patients who have recently undergone SCT. The mechanism of this acquired deficiency state remains to be defined.

Download full-text


Available from: Amir Ahmed Toor, Jul 02, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary toxicity that occurs in 1-21% of patients following bone marrow transplantation. The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A greater understanding of the mechanism by which rFVIIa restores hemostasis has recently become available; with in vitro evidence supporting that the thrombin burst achieved by rFVIIa is independent of the presence or binding to tissue factor. This insight has suggested a range of other potential clinical uses for the drug; including the setting of pulmonary hemorrhage. We review our experience with using rFVIIa for treatment of DAH in a patient with acute myelogenous leukemia following a matched unrelated donor bone marrow transplant. Boluses of 90 microg/kg rFVIIa were given every 3 h x 4 doses/day, concurrently with high-dose corticosteroids and maintenance of a platelet count >50 000/mm(3). Rapid clinical and radiological improvement was noted within several doses of rFVIIa, with discontinuation of the drug after eight doses. However, the patient's clinical condition began to rapidly deteriorate following cessation of rVIIa, resulting in reinstitution of therapy 24 h later. The patient again exhibited rapid clinical improvement; and rFVIIa was continued for an additional 16 doses with no further evidence of pulmonary hemorrhage noted. No toxicity or adverse events were observed with rFVIIa treatment. Our experience indicates that rFVIIa may be an effective treatment option for DAH post bone marrow transplant; although further clinical studies are needed before recommendations can be made regarding off label use of rFVIIa in this clinical setting.
    Bone Marrow Transplantation 12/2002; 30(12):975-8. DOI:10.1038/sj.bmt.1703731 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The coagulation factor VII is a vitamin K dependant glycoprotein synthesized by the hepatocyte. It has a crucial role in the onset of the coagulation processes. The factor VII gene is localized on chromosome 13, which composes nine exons and eight introns. The genetic background of factor VII is heterogeneous and several types of mutations have been reported, with a variety of clinical consequences. In the present study, we investigated the R353Q polymorphism and its relationship with the plasma factor VII level as well as its clinical outcome.Patients. – Fifty-two patients with a plasma factor VII level lower than 60% and 120 controls with a plasma factor VII higher than 60% were taken among the Tunisian population.Methods. – The factor VII activity was assayed with clotting techniques whereas the factor VII antigen was determined by an ELISA assay. Genetic analysis of the R353Q mutation in the factor VII gene was performed by the DNA extraction from whole blood, PCR products and gel analysis on 6% polyacrylamide gel electrophoresis.Results. – Normal homozygous (88.5%) were (M1M1) with a plasma factor VII level of 49.5 ± 29.9%. Heterozygous (7.7%) were (M1M) with plasma factor VII level of 19.52 ± 14%, whereas only 3.8% were homozygous for the mutated allele (M2M2) with a plasma factor VII level of 5.2 ± 0.7%. Among the controls, the prevalence of the normal homozygous genotype (M1M1) is also high (78%) whereas the genotypes M1M2 and M2M2 prevalences were, respectively, 20% and 1.6%. The CRM– phenotype was the most frequent (57.7%) in comparison with the two other phenotypes CRM+ and CRMRed (30.8% and 11.5%), respectively. The CRM phenotype seems to be correlated with occurrence of hemorrhagic disorders, 38.5% of the patients presented with bleeding, likewise a correlation exists between plasma factor VII level and the R353Q mutation.
    Immuno-analyse & Biologie Spécialisée 02/2004; 19(1):66-70. DOI:10.1016/j.immbio.2003.12.002 · 0.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acquired isolated FVII deficiency not due to vitamin K deficiency or liver disease is rare and often associated with severe bleeding. We present a case of transient acquired factor VII deficiency associated with major bleeding, successfully treated with twice daily intermittent intravenous recombinant activated factor VII (rFVIIa) (NovoSeven; Novo Nordisk). The severe transient reduction in factor VII coagulant activity (FVII:C) levels, unresponsive to fresh frozen plasma and vitamin K administration, raise the possibility of an acquired inhibitor to factor VII. However, no inhibitor to factor VII could be demonstrated using protein G sepharose adsorption, or a Bethesda assay using IgG purified from patient plasma. There are few reports of the use of rFVIIa in this setting and this case suggests that rFVIIa is effective therapy, and should be considered early when acquired factor VII deficiency is associated with severe bleeding.
    Blood Coagulation and Fibrinolysis 07/2004; 15(4):347-51. DOI:10.1097/00001721-200406000-00010 · 1.40 Impact Factor
Show more